CYMABAY THERAPEUTICS, INC.

(CBAY)
  Report
Real-time Estimate Cboe BZX  -  05/27 03:31:19 pm EDT
2.010 USD   +2.03%
05/23CymaBay Therapeutics Says Seladelpar Reduces Need for Liver Transplants
MT
05/23CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
AQ
05/23CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
1.98(c) 1.91(c) 1.92(c) 1.97(c) 2 Last
405 546 447 302 568 783 331 401 228 517 Volume
-5.71% -3.54% +0.52% +2.60% +1.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4,29 M - -
Net income 2022 -107 M - -
Net cash position 2022 38,8 M - -
P/E ratio 2022 -1,56x
Yield 2022 -
Sales 2023 7,86 M - -
Net income 2023 -120 M - -
Net cash position 2023 130 M - -
P/E ratio 2023 -1,48x
Yield 2023 -
Capitalization 163 M 163 M -
EV / Sales 2022 28,9x
EV / Sales 2023 4,13x
Nbr of Employees 59
Free-Float 95,6%
More Financials
Company
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in... 
More about the company
Ratings of CymaBay Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C+
More Ratings
All news about CYMABAY THERAPEUTICS, INC.
05/23CymaBay Therapeutics Says Seladelpar Reduces Need for Liver Transplants
MT
05/23CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients fo..
AQ
05/23CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patie..
CI
05/18B. Riley Lowers Cymabay Therapeutics' Price Target to $8 from $10 to Account for Slight..
MT
05/16HC Wainwright Lowers Cymabay Therapeutics's Price Target to $10 From $12, Maintains Buy..
MT
05/12Cymabay Therapeutics Q1 Loss Widens, Sees Enough Funds Through 2023 -- Stock Rises 7% A..
MT
05/12TRANSCRIPT : CymaBay Therapeutics, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12CYMABAY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/12CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update
AQ
05/12CymaBay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/12EARNINGS REACTION HISTORY : CymaBay Therapeutics Inc, 60.0% Follow-Through Indicator, 17.9..
MT
05/11CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022
AQ
05/05CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May..
AQ
04/19CYMABAY THERAPEUTICS, INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
04/19CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nomina..
CI
More news
News in other languages on CYMABAY THERAPEUTICS, INC.
05/23Selon CymaBay Therapeutics, le Seladelpar réduit le besoin de transplantations hépatiqu..
05/23CymaBay Therapeutics, Inc. Présente de nouvelles conclusions selon lesquelles le traite..
05/12La perte de Cymabay Therapeutics au premier trimestre s'accentue, mais l'entreprise est..
05/12CymaBay Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 m..
05/12HISTORIQUE DES RÉACTIONS AUX BÉNÉFIC : CymaBay Therapeutics Inc, indicateur de suivi à 60,..
More news
Analyst Recommendations on CYMABAY THERAPEUTICS, INC.
More recommendations
Chart CYMABAY THERAPEUTICS, INC.
Duration : Period :
CymaBay Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYMABAY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 1,92 $
Average target price 10,25 $
Spread / Average Target 434%
EPS Revisions
Managers and Directors
Sujal Shah President & Chief Executive Officer
Daniel Menold Controller
Robert James Wills Chairman
Charles A. McWherter Senior Vice President-Research
Dennis D. Kim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CYMABAY THERAPEUTICS, INC.-43.20%163
GILEAD SCIENCES, INC.-10.47%81 543
REGENERON PHARMACEUTICALS, INC.9.40%74 440
VERTEX PHARMACEUTICALS23.33%69 269
WUXI APPTEC CO., LTD.-25.70%39 423
BIONTECH SE-40.00%37 588